Cargando…

Emricasan Ameliorates Portal Hypertension and Liver Fibrosis in Cirrhotic Rats Through a Hepatocyte‐Mediated Paracrine Mechanism

In cirrhosis, liver microvascular dysfunction is a key factor increasing hepatic vascular resistance to portal blood flow, which leads to portal hypertension. De‐regulated inflammatory and pro‐apoptotic processes due to chronic injury play important roles in the dysfunction of liver sinusoidal cells...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gracia‐Sancho, Jordi, Manicardi, Nicolò, Ortega‐Ribera, Martí, Maeso‐Díaz, Raquel, Guixé‐Muntet, Sergi, Fernández‐Iglesias, Anabel, Hide, Diana, García‐Calderó, Héctor, Boyer‐Díaz, Zoe, Contreras, Patricia C., Spada, Alfred, Bosch, Jaime
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6601324/ https://www.ncbi.nlm.nih.gov/pubmed/31304452 http://dx.doi.org/10.1002/hep4.1360

Ejemplares similares

4 in 1: Antibody‐free protocol for isolating the main hepatic cells from healthy and cirrhotic single rat livers
por: Fernández‐Iglesias, Anabel, et al.
Publicado: (2018)

Advances in therapeutic options for portal hypertension
por: Vilaseca, Marina, et al.
Publicado: (2018)

Mechanobiology of portal hypertension
por: Felli, Eric, et al.
Publicado: (2023)

Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies
por: de Mesquita, Fernanda Cristina, et al.
Publicado: (2017)

Regression of portal hypertension: underlying mechanisms and therapeutic strategies
por: Selicean, Sonia, et al.
Publicado: (2021)

Emricasan (IDN‐6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension
por: Garcia‐Tsao, Guadalupe, et al.
Publicado: (2018)

A Nutraceutical Rich in Docosahexaenoic Acid Improves Portal Hypertension in a Preclinical Model of Advanced Chronic Liver Disease
por: Boyer-Diaz, Zoe, et al.
Publicado: (2019)

The Hepatic Sinusoid in Chronic Liver Disease: The Optimal Milieu for Cancer
por: Gibert-Ramos, Albert, et al.
Publicado: (2021)

Efficacy and Safety of Emricasan in Liver Cirrhosis and/or Fibrosis
por: Mu, Li-ya, et al.
Publicado: (2021)

New Rat Model of Advanced NASH Mimicking Pathophysiological Features and Transcriptomic Signature of The Human Disease
por: Maeso-Díaz, Raquel, et al.
Publicado: (2019)

Nuclear deformation mediates liver cell mechanosensing in cirrhosis
por: Guixé-Muntet, Sergi, et al.
Publicado: (2020)

Effects of aging on liver microcirculatory function and sinusoidal phenotype
por: Maeso‐Díaz, Raquel, et al.
Publicado: (2018)

Review article: vascular effects of PPARs in the context of NASH
por: Guixé‐Muntet, Sergi, et al.
Publicado: (2022)

Oxidative Stress in Chronic Liver Disease and Portal Hypertension: Potential of DHA as Nutraceutical
por: Boyer-Diaz, Zoe, et al.
Publicado: (2020)

Resemblance of the human liver sinusoid in a fluidic device with biomedical and pharmaceutical applications
por: Ortega‐Ribera, Martí, et al.
Publicado: (2018)

Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non‐alcoholic fatty liver disease
por: Shiffman, Mitchell, et al.
Publicado: (2018)

Non-Cirrhotic Portal Hypertension in Systemic Lupus Erythematosus
por: Suárez-Díaz, Silvia, et al.
Publicado: (2023)

D020 ROLE OF CELLULAR CASPASES AND THERAPEUTIC POTENTIAL OF A PAN-CASPASE INHIBITOR, EMRICASAN, IN COVID-19.
por: Alpan, O., et al.
Publicado: (2021)

Effects of warm ischemia and reperfusion on the liver microcirculatory phenotype of rats: underlying mechanisms and pharmacological therapy
por: Hide, Diana, et al.
Publicado: (2016)

Emerging Therapeutic Targets for Portal Hypertension
por: Felli, Eric, et al.
Publicado: (2023)

Wall shear stress in portal vein of cirrhotic patients with portal hypertension
por: Wei, Wei, et al.
Publicado: (2017)

Management of Portal Vein Thrombosis in Cirrhotic Patients
por: Amitrano, Lucio, et al.
Publicado: (2009)

Gastrointestinal Bleeding in Cirrhotic Patients with Portal Hypertension
por: Biecker, Erwin
Publicado: (2013)

Causes and Management of Non-cirrhotic Portal Hypertension
por: Gioia, Stefania, et al.
Publicado: (2020)

Interaction between NO and COX pathways modulating hepatic endothelial cells from control and cirrhotic rats
por: Rosado, Eugenio, et al.
Publicado: (2012)

Severity of Hepatocyte Damage and Prognosis in Cirrhotic Patients Correlate with Hepatocyte Magnesium Depletion
por: Parisse, Simona, et al.
Publicado: (2023)

Nitro-oxidative stress, VEGF and MMP-9 in patients with cirrhotic and non-cirrhotic portal hypertension
por: MUTI, LEON ADRIAN, et al.
Publicado: (2015)

Cardiac dysfunction in cirrhotic portal hypertension with or without ascites
por: Dadhich, Sunil, et al.
Publicado: (2014)

Idiopathic non-cirrhotic portal hypertension: a review
por: Schouten, Jeoffrey NL, et al.
Publicado: (2015)

The beneficial effects of curcumin in cirrhotic rats with portal hypertension
por: Hsu, Shao-Jung, et al.
Publicado: (2017)

Research progress on signaling pathways in cirrhotic portal hypertension
por: Xu, Wen, et al.
Publicado: (2018)

Cirrhotic portal hypertension: From pathophysiology to novel therapeutics
por: Gunarathne, Lakmie S, et al.
Publicado: (2020)

Non-cirrhotic portal hypertension in an ankylosing spondylitis patient
por: Park, Sukki, et al.
Publicado: (2018)

Non-cirrhotic portal vein thrombosis – therapeutic challenge
por: Sarquis, Lucas Mansano, et al.
Publicado: (2022)

Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension
por: Uschner, Frank E., et al.
Publicado: (2015)

Aging Influences Hepatic Microvascular Biology and Liver Fibrosis in Advanced Chronic Liver Disease
por: Maeso-Díaz, Raquel, et al.
Publicado: (2019)

The Impact of Partial Splenic Embolization on Portal Hypertensive Gastropathy in Cirrhotic Patients with Portal Hypertension
por: Saeki, Michio, et al.
Publicado: (2023)

Splenic arteriovenous fistula leading to non-cirrhotic portal hypertension: a case report: Splenic arteriovenous fistula leading to non-cirrhotic portal hypertension
por: Abou Yassine, Ahmad, et al.
Publicado: (2023)

Non-Cirrhotic Portal Hypertension in Human Immunodeficiency Virus-Infected Patients: A New Challenge in Antiretroviral Therapy Era
por: Álvarez Díaz, Hortensia, et al.
Publicado: (2011)

Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension
por: Kreisel, Wolfgang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7plb5l98mvheik18s4l0eun7mo